NEO6860
/ AazeinTx
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 17, 2021
adMare and AazeinTx Inc. Sign Global Exclusive Agreement for Promising Acute Asthma Treatment (NEO6860)
(Canada Newswire)
- "adMare BioInnovations ('adMare') and AazeinTx Inc. ('AazeinTx') have closed a global exclusive licensing transaction for a promising acute asthma treatment. Under the agreement, AazeinTx has acquired all rights to NEO6860...Based on Wilson's preclinical research, AazeinTx proposes to bring a pill-based form of NEO6860 to humans as a rapid, effective, and disruptive technology to treat asthma."
Licensing / partnership • Asthma • Respiratory Diseases
January 15, 2020
Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis.
(PubMed, Pharmacol Ther)
- "We also conducted a meta-analysis of T data from human trials and found that polymodal TRPV1 antagonists (ABT-102, AZD1386, and V116517) increase T, whereas the mode-selective blocker NEO6860 does not. Several strategies of harnessing the thermoregulatory effects of TRPV1 antagonists in humans are discussed."
Journal • Retrospective data • Review
1 to 2
Of
2
Go to page
1